# Voyager Therapeutics, Inc. (VYGR) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Voyager Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/VYGR/mda/fy2025/): filed 2026-03-09; accession 0001104659-26-025197 (https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/vygr-20251231x10k.htm); latest 10-K
- [FY 2024 MD&A](/company/VYGR/mda/fy2024/): filed 2025-03-11; accession 0001558370-25-002703 (https://www.sec.gov/Archives/edgar/data/1640266/000155837025002703/vygr-20241231x10k.htm)
- [FY 2023 MD&A](/company/VYGR/mda/fy2023/): filed 2024-02-28; accession 0001558370-24-001988 (https://www.sec.gov/Archives/edgar/data/1640266/000155837024001988/vygr-20231231x10k.htm)
- [FY 2022 MD&A](/company/VYGR/mda/fy2022/): filed 2023-03-07; accession 0001558370-23-002989 (https://www.sec.gov/Archives/edgar/data/1640266/000155837023002989/vygr-20221231x10k.htm)
- [FY 2021 MD&A](/company/VYGR/mda/fy2021/): filed 2022-03-08; accession 0001558370-22-003015 (https://www.sec.gov/Archives/edgar/data/1640266/000155837022003015/vygr-20211231x10k.htm)

Back to /company/VYGR/